About the Journal

Immunology Research and Perspectives (IRP) is an international, peer-reviewed, open-access journal dedicated to advancing research into the fundamental theory, disease mechanisms, and translational applications of the immune system. Published Semi-annually online by  Cultech Publishing Sdn. Bhd., the journal aims to integrate fundamental immunology discoveries with clinical and therapeutic approaches to address global health challenges.

Aim and Scope:
IRP focuses on cutting-edge research in immune regulation, host-pathogen interactions, immunotherapy, and precision immunology. The aim and scope of the journal includes, but is not limited to, the following areas:

  • Molecular and cellular immune mechanisms in health and disease
  • Autoimmunity, inflammation, and immune tolerance networks
  • Vaccinology and emerging infectious disease defense strategies
  • Cancer immunology and novel immunotherapies (e.g., checkpoint inhibitors, CAR-T therapy)
  • Systems immunology, omics technologies, and computational modeling of immune responses

The journal serves as a platform for interdisciplinary collaboration, connecting immunologists, clinicians, and biotechnologists to address global challenges in epidemic preparedness, autoimmune diseases, cancer treatment, and vaccine development.

Open Access: This journal operates under a "gold" Open Access model, providing free access to all readers.  The Article Processing Charges (APC) for all article types (research, review, case reports) is $0, and the content will be published under a CC BY license. IRP offers full or partial fee waivers for eligible articles from low- and middle-income economies. For specific APC policies, please refer to the Open Access policy section.

General Information

1st Year Published: 2025

Frequency: Semi-annually

Issues Per Year: 2

Country / Region: Malaysia

Primary Language: English

Publisher information: Cultech Publishing Sdn. Bhd.

The manuscript processing cycle is approximately 12 weeks from submission to acceptance.